10x Genomics, Inc. Class A Common Stock (TXG) is a publicly traded Healthcare sector company. As of September 4, 2026, TXG trades at $61.76 with a market cap of $8.03B and a P/E ratio of -106.05. TXG moved -1.98% today. Year to date, TXG is +280.38%; over the trailing twelve months it is +365.88%. Its 52-week range spans $6.78 to $66.94. Analyst consensus is buy with an average price target of $50.36. Rallies surfaces TXG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
TXG financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TXG recently traded at $61.76. Market cap is $8.03B. P/E ratio is -106.05. Revenue is $616.91M.
| Metric | Value |
|---|---|
| Price | $61.76 |
| Market Cap | $8.03B |
| P/E Ratio | -106.05 |
| EPS | $-0.59 |
| Dividend Yield | 0.00% |
| 52-Week High | $66.94 |
| 52-Week Low | $6.78 |
| Volume | 222.00K |
| Avg Volume | 0 |
| Revenue (TTM) | $616.91M |
| Net Income | $-75.13M |
| Gross Margin | 70.03% |
13 analysts cover TXG: 0 strong buy, 6 buy, 7 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $50.36.